Frantz Viral Therapeutics

Frantz Viral Therapeutics (FVT) is dedicated to changing the landscape of care for patients with HPV-induced precancers. In order to achieve that goal, we are focused on conducting the clinical trials necessary to gain regulatory approvals to offer our therapies to the general public. We believe this approach is the quickest way to make our therapies broadly available to patients. At the same time, we understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have access to alternative therapies to treat their HPV-associated lesion or opportunities to enroll in other clinical trials.

FVT occasionally provides pre-approval access to its treatments in limited expanded access protocols managed and conducted by collaborating physicians. If your physician believes you may benefit from participating in an expanded access protocol, and you do not have alternative treatment options, please have her/him contact us at fvtinfo@frantzgroup.com. We will acknowledge receipt of your request in approximately 5 business days. Requests will be evaluated on a case-by-case basis. The request will be evaluated on a number of points including, but not limited to, assessing the supply of treatment, number of spots remaining in available expanded access protocols, and ensuring the expanded access protocol will not negatively impact or delay the conduct of clinical research. The treatment protocols must conform to the existing trial(s) study protocols with possible exceptions related to inclusion/exclusion criteria.

Participation in our clinical trials is the best way to access the treatments for those who are eligible. To learn more about our ongoing clinical studies, please visit www.clinicaltrials.gov.

FVT reserves the right to revise this statement at any time.